Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, discusses socioeconomic barriers, such as financial constraints, unstable housing, stressful living situations, and demanding work schedules, can hinder diabetes self-care, requiring healthcare providers to approach patients with empathy when addressing these challenges.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCC, discusses how technological advancements in diabetes care, such as continuous glucose monitors, can help patients better manage their disease.

Estay Greene, PharmD, MBA, offers key takeaways and provides closing thoughts on remaining unmet needs in the treatment of patients with diabetes.

Insights on how payers can allocate their resources to best improve outcomes for patients with diabetes.

Payer perspectives on the challenges and advantages of integrating continuous glucose monitoring into diabetes management programs, highlighting the navigation of prior authorization requirements.

An expert on the treatment of diabetes offers insights on utilizing data to reveal disparities in care based on factors such as demographics and location.

Estay Greene, PharmD, MBA, outlines the main barriers that need to be addressed from a payer perspective in the treatment of high-risk patients with diabetes.

Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.

Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.

A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.

Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.

Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.

Dario is using Sanofi’s research infrastructure to evaluate its digital health products.

Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.

Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.

Sara Izadi, Pharm.D., of Capital Rx, talks about Rx Reverse, an integrated clinical program designed to help members reverse diabetes and fight obesity.

Professional development should take steps to incorporate outreach into medical school curriculums, say Rosemay Michel, D.P.M., and Gary M. Rothenberg, D.P.M. "Students must learn what motivates people to make healthy choices in their daily lives, including the influences of schools, faith-based groups, social media and extended family on personal decision-making," argue Michel and Rothenberg.

An analysis by Biosimilars Council has found that the reference product Lantus accounts for 54% of new prescriptions and is 78% of total market volume but demand for the unbranded interchangeable insulin glargine is increasing.

Longer-acting growth hormone reduces frequency of injections. It will be available in August.

In two small studies, patients were able to be free from insulin injections for a year or more.

Jardiance and Synjardy are the first SGLT2 inhibitors approved for children with type 2 diabetes.

A bipartisan Senate bill, Affordable Insulin Now Act of 2023, would require plans to cover insulin for no more than $35 per month.

Focusing on preventing diabetes and reducing disparities across populations, Dr Greene highlights ways to improve affordability and access to new treatment technologies.

CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens.

The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.

The lower prices will take effect on Jan. 1, 2024, on both pre-filled pens and vials of basal, bolus and pre-mix insulins, including Levemir, Novolin, NovoLog and NovoLog Mix 70/30.